Comparative Pharmacology
Head-to-head clinical analysis: NAPROXEN SODIUM versus TOLECTIN 600.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NAPROXEN SODIUM versus TOLECTIN 600.
NAPROXEN SODIUM vs TOLECTIN 600
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis.
220-550 mg orally twice daily; maximum 1375 mg/day.
600 mg orally three times daily; maximum 1800 mg/day.
None Documented
None Documented
12–17 hours (terminal); allows twice-daily dosing; prolonged in elderly and renal impairment
Terminal elimination half-life is approximately 5 hours (range 4-6 hours) in healthy adults; prolonged in renal impairment.
Renal: 95% (as unchanged drug, conjugated naproxen, and 6-O-desmethyl naproxen); Fecal: <5%
Renal: approximately 90% as metabolites and conjugates; biliary/fecal: minor (less than 10%)
Category D/X
Category C
NSAID
NSAID